What is it about?
In the context of precision medicine, disease treatment requires individualized strategies based on the underlying molecular characteristics to overcome therapeutic challenges posed by heterogeneity. For this purpose, it is essential to develop new biomarkers to diagnose, stratify, or possibly prevent diseases. Plasma is an available source of biomarkers that greatly reflects the physiological and pathological conditions of the body. An increasing number of studies are focusing on proteins and peptides, including many involving the Human Proteome Project (HPP) of the Human Proteome Organization (HUPO), and proteomics and peptidomics techniques are emerging as critical tools for developing novel precision medicine preventative measures. Excitingly, the emerging plasma proteomics and peptidomics toolbox exhibits a huge potential for studying pathogenesis of diseases (e.g., COVID-19 and cancer), identifying valuable biomarkers and improving clinical management.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Herein, we summarize the recent advances in plasma proteomics and peptidomics with a focus on their emerging roles in COVID-19 and cancer research, aiming to emphasize the significance of plasma proteomics and peptidomics in clinical applications and precision medicine.
Perspectives
In summary, there is no question that proteomics and peptidomics are now feasible and open up exciting new paths for biomarkers from laboratory discovery to clinical application. While in many ways the field is still in its infancy, we firmly believe that, with the continuing unremitting efforts of scientists all around the world, plasma proteomics and peptidomics will become a frontier of next-generation disease diagnosis technology, and will support the role of precision medicine in health and disease.
Bo He
Sichuan University
Read the Original
This page is a summary of: Clinical applications of plasma proteomics and peptidomics: Towards precision medicine, PROTEOMICS - CLINICAL APPLICATIONS, May 2022, Wiley,
DOI: 10.1002/prca.202100097.
You can read the full text:
Contributors
The following have contributed to this page
